Skip to content
value.today
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

BOLT
$16 Mmarket cap on Oct 26, 2026-65.2% since Jan 2024
1M
+69.1%
Compare
World rank
#24,854
Revenue
$8 M
For year ending December-2025
Net income
$-33 M
-433.5% margin
SEC filing
Employees
23
As of December 31, 2025
SEC filing

Bolt Biotherapeutics, Inc. in brief

Bolt Biotherapeutics, Inc. is a listed company in the Biotechnology industry, based in Redwood City, California, USA. It was founded in 2015. Its market value was $16 M on 26 October 2026, which makes it the 24,854th largest listed company in the world and the 4,196th largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $33 M. It employs about 23 people. Its shares trade under the symbol BOLT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Bolt Biotherapeutics, Inc.

Our mission is to harness the power of the immune system to improve lives and eradicate cancer. This often means that our product candidates take new and unproven approaches to treating cancer. We believe that taking smart risks is critical to making breakthroughs. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our various approaches use pattern recognition receptors expressed by the innate immune system to help the body eliminate tumor cells as part of a productive anti-cancer response. Our proprietary Boltbody™ Immune-Stimulating Antibody Conjugate, or ISAC, platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer activity with acceptable tolerability. Having explored more than one thousand distinct linker-payloads and multiple tumor targets, we know the importance of both the linker-payload and the antibody and have developed a library of linker-payloads for use in our own development programs and in our collaborations.

From the company's annual report filed with the US SEC: read the report

Bolt Biotherapeutics, Inc. timeline

5 events, 2015–2023
  1. 2015
  2. 🏁
    · approximate
    Founded
  3. ✎
    Renamed Bolt Biotherapeutics, Inc.
    Formerly Bolt Therapeutics, Inc..
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 5 February 2021; shares registered for exchange trading on 2 February 2021.
  7. 2023
  8. 💰
    Record revenue of $8 million
    FY2023, the highest of the 6 years on record.

Events of Bolt Biotherapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$38 M$76 M$114 M$152 M2023202420252026

World rank over time

▼ down 4,059 places since 2022
2022-01-07: #20807#20,80720222022-12-25: #25247#25,24720222023-07-30: #25337#25,33720232024-01-05: #25258#25,25820242026-03-08: #12893#12,89320262026-08-01: #23448#23,44820262026-09-23: #25981#25,98120262026-10-26: #24866#24,8662026

Rank in USA: #4,146 (Jan 2022) · #4,794 (Dec 2022) · #4,742 (Jul 2023) · #4,092 (Jan 2024) · #2,400 (Mar 2026) · #4,099 (Aug 2026) · #4,263 (Sep 2026) · #4,198 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
3.5×
Price / book
0.6×
Free cash flow yield
-244.2%
Net margin (TTM)
-610.2%
Operating margin
-469.0%
Return on equity
-108.5%
Liabilities / assets
53.3%
Revenue growth
+0.1%
R&D / revenue
370.5%
Revenue per employee
$335 K
Profit per employee
$-1.5 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $0M, net income $-61M$0MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-99M$1MFY21Fiscal year ending Dec 2022: revenue $6M, net income $-88M$6MFY22Fiscal year ending Dec 2023: revenue $8M, net income $-69M$8MFY23Fiscal year ending Dec 2024: revenue $8M, net income $-63M$8MFY24Fiscal year ending Dec 2025: revenue $8M, net income $-33M$8MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$8M+0.1%$-36M$-33M-433.5%
Dec 2024$8M-2.4%$-73M$-63M-820.8%
Dec 2023$8M+37.5%$-76M$-69M-878.2%
Dec 2022$6M+354.8%$-90M$-88M-1537.5%
Dec 2021$1M+447.8%$-93M$-99M-7824.6%
Dec 2020$0M—$-49M$-61M-26404.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-40M$0M$-40M$-17.85—
Dec 2024$-61M$0M$-61M$-33.06—
Dec 2023$-70M$0M$-70M$-1.83—
Dec 2022$-77M$2M$-78M$-2.36—
Dec 2021$-57M$2M$-59M$-2.97—
Dec 2020$-47M$3M$-51M$-28.89—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$5M
Net income, trailing 12 months
$-29M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue $1M, net income $-11M$1MMar ’25Three months to Jun 2025: revenue $2M, net income $-9M$2MJun ’25Three months to Sep 2025: revenue $2M, net income $-7M$2MSep ’25Three months to Dec 2025 (from the annual report): revenue $3M, net income $-7M$3MDec ’25Three months to Mar 2026: revenue $0M, net income $-7M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-8M$0MJun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Bolt Biotherapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$8 M
Operating income
$-36 M
Net income
$-33 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$57 M
Total liabilities
$30 M
Total equity
$27 M

As of December-2025

Top 23 institutional investors in Bolt Biotherapeutics, Inc.#

As of Sep 30, 2026
23 institutions held 576,383 shares (about 29.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 26.0%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 23 largest institutional investors in Bolt Biotherapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Sofinnova Investments, Inc.137,7210 (0.00%)7.15%$1 MNov 16, 2026
2Renaissance Technologies LLC92,925-5,700 (-5.78%)4.82%$0 MNov 12, 2026
3Vivo Capital, LLC72,4140 (0.00%)3.76%$0 MNov 13, 2026
4T3 Companies, LLC38,0000 (0.00%)1.97%$0 MOct 22, 2026
5Board of Trustees of The Leland Stanford Junior University35,9770 (0.00%)1.87%$0 MNov 16, 2026
6Pfizer Inc31,3050 (0.00%)1.63%$0 MNov 12, 2026
7Lynx1 Capital Management LP30,8000 (0.00%)1.60%$0 MNov 16, 2026
8Nano Cap New Millennium Growth Fund L P27,5000 (0.00%)1.43%$0 MNov 13, 2026
9Citadel Advisors LLC18,300-38,603 (-67.84%)0.95%$0 MNov 16, 2026
10Susquehanna International Group, LLP16,838New0.87%$0 MNov 16, 2026
11Shay Capital LLC16,526+1,088 (+7.05%)0.86%$0 MNov 16, 2026
12Geode Capital Management, LLC15,797-3,322 (-17.38%)0.82%$0 MNov 6, 2026
13Vanguard Fiduciary Trust Co15,533+12,438 (+401.87%)0.81%$0 MNov 13, 2026
14BlackRock, Inc.9,7110 (0.00%)0.50%$0 MNov 13, 2026
15Vanguard Capital Management LLC7,0600 (0.00%)0.37%$0 MNov 13, 2026
16Nan Fung Group Holdings Ltd5,0000 (0.00%)0.26%$0 MNov 13, 2026
17Morgan Stanley4,167+1,022 (+32.50%)0.22%$0 MNov 13, 2026
18Tower Research Capital LLC (TRC)500-1,210 (-70.76%)0.03%$0 MNov 16, 2026
19Jpmorgan Chase & Co290+248 (+590.48%)0.02%$0 MNov 12, 2026
20SBI Securities Co., Ltd.10-120 (-92.31%)0.00%$0 MOct 22, 2026
21Barclays PLC60 (0.00%)0.00%$0 MNov 6, 2026
22UBS Group AG2-253 (-99.22%)0.00%$0 MNov 10, 2026
23Citigroup Inc1-40 (-97.56%)0.00%$0 MNov 4, 2026

Mutual funds holding Bolt Biotherapeutics, Inc.#

6 funds hold shares worth $0 M (about 1.6% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Bolt Biotherapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC17,060$0 M0.89%<0.01%+98%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC5,348$0 M0.28%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.7,060$0 M0.37%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,699$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC143$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors89$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Bolt Biotherapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$634 K
7 purchases, 3 insiders
Sold, 12 months
$128 K
9 sales, 3 insiders
Net, 12 months
$506 K
open market only
Insiders on file
17
since
$629 K-$212 K$0Nov 2023: bought $0 (0 trades), sold $212 K (24 trades)Nov 23Dec 2023: bought $9 K (5 trades), sold $0 (0 trades)Jun 2024: bought $2 K (2 trades), sold $0 (0 trades)JunDec 2024: bought $1 K (2 trades), sold $0 (0 trades)Jun 2025: bought $686 (2 trades), sold $0 (0 trades)JunDec 2025: bought $576 (2 trades), sold $0 (0 trades)Jun 2026: bought $4 K (2 trades), sold $0 (0 trades)JunSep 2026: bought $0 (0 trades), sold $128 K (9 trades)Nov 2026: bought $629 K (3 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Bolt Biotherapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Coastlands Capital LP10% ownerBuyindirect+20,000$5.750$115 K515,510Form 4
filed Coastlands Capital LP10% ownerBuyindirect+33,094$5.890$195 K495,510Form 4
filed Coastlands Capital LP10% ownerBuyindirect+50,000$6.380$319 K462,416Form 4
filed Sheila GujrathiChief Strategy Officer, DirectorGrant or award+72,766——72,766Form 4
filed Sheila GujrathiChief Strategy Officer, DirectorGrant or awardindirect+13,055——13,055Form 4
filed Grant YonehiroChief Operating OfficerSell-6,850$3.240$22 K17,269Form 4
filed William P. QuinnPresident, CEO and CFO, DirectorSell-9,132$3.240$30 K25,384Form 4
filed Sarah NemecSenior VP, Finance and PAOSell-4,077$3.240$13 K17,082Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Bolt Biotherapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
47,382
2.5% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 20-for-1 split

Trading halts

  • 2026-10-23 13:57 UTC, code LUDP, resumed 14:02 UTC
  • 2026-10-23 12:40 UTC, code T3, resumed 13:50 UTC
  • 2025-06-06 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 11,432 shares at $6.27
  • : 9 shares at $3.71
  • : 57 shares at $3.85
  • : 1,401 shares at $3.69
  • : 285 shares at $4.74

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Bolt Biotherapeutics, Inc. scorecard#

Passes 9 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median3.5×Price to sales 3.5× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year0.1%Revenue up 0.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years10.3%10.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median10.3%10.3% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-17.85 vs -33.06Diluted EPS -17.85 in fiscal 2025 against -33.06 the year before (report's currency).
    • ✓Net income higher than five years earlier-$33 M-$33 M in fiscal 2025 against -$61 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$33 MNet income -$33 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-469.0%-469.0% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-79.8%-79.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-469.0%-469.0% in fiscal 2025 against -1576.3% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.59 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-12.55Z-score -12.55 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-2.0%Diluted shares down 2.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Bolt Biotherapeutics, Inc.'s statements, beside the median of Biotechnology.

Bolt Biotherapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-469.0%-60.5%
Net margin-433.5%-68.9%
Return on equity-79.8%-61.0%
Revenue growth, 3 years a year10.4%12.9%
Revenue growth0.1%15.8%
Free cash flow margin-518.4%-61.5%

3of 7on the Piotroski tests of financial strength

  • Net loss of $33 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$40 million.
  • The share count fell 2.0% in the year (buybacks).

Bolt Biotherapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Bolt Biotherapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue7.77.77.95.71.30.2
Research and development295762737640
General and administrative14182323189.1
Operating expenses448184969449
Operating income−36−73−76−90−93−49
Other non-operating income (expense)2.79.97.02.2−5.8−12
Income before tax−33−63————
Income tax000000
Net income including minority interests−33−63−69−88−99−61
Net income attributable to shareholders−33−63−69−88−99−61
Earnings per share, basic-17.85-33.06r-1.83-2.36-2.97-28.89
Earnings per share, diluted-17.85-33.06r-1.83-2.36-2.97-28.89
Shares, weighted average (basic)1.91.9r383733r2.0
Shares, weighted average (diluted)1.91.9r3837332.1
Balance sheet
Cash and cash equivalents127.2119.2275.5
Short-term investments16409116015917
Other current assets2.62.73.53.92.92.5
Current assets305110617318925
Property, plant and equipment1.23.15.06.56.24.1
Right-of-use (leased) assets192219222412
Long-term investments4.323262485—
Total assets5710016022830847
Accounts payable1.41.53.03.63.61.6
Current liabilities8.41620232111
Lease liabilities (non-current)20231720229.4
Total liabilities304247565846
Retained earnings−461−427−364−295−207−108
Shareholders' equity2757113172250−105
Total liabilities and equity5710016022830847
Shares outstanding1.91.9r3838372.1
Cash-flow statement
Depreciation and amortization1.31.81.91.71.20.6
Share-based compensation2.87.49.29.68.51.4
Cash from operating activities−40−61−70−77−57−47
Capital expenditure−0.1−0.0−0.2−2.0−2.3−3.3
Cash from investing activities44587158−232−21
Shares issued0.00.10.30.51.30.3
Cash from financing activities0.00.10.30.531140
Change in cash4.5−3.61.8−1822−28
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Bolt Biotherapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Bolt Biotherapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Bolt Biotherapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Restructuring 2 · Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 2 · Agreement ended 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 3 · Shareholder vote 3 · Results announced 11

Bolt Biotherapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Acquisition or sale completedDirectors and officersMaterial agreementAgreement endedUnregistered share saleBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Restructuring8-K
Results announced8-K
Delisting noticeBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Shareholder vote8-K
RestructuringAcquisition or sale completedDirectors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

6 private funding rounds before listing

Private share sales · funding history

Private share sales of Bolt Biotherapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$15 MNo. 6$10 to $50 million1equitySEC
Jun 2020$94 MNo. 5$50 to $250 million17equitySEC
Jul 2019$40 MNo. 4$10 to $50 million11equitySEC
Jul 2018$13 MNo. 3$10 to $50 million11equitySEC
Feb 2018$6 MNo. 2$2 to $10 million6equitySEC
Sep 2016$10 MNo. 1$10 to $50 million6equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Bolt Biotherapeutics, Inc.#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $180 K a year.

Certified, FY2022
1
#2,057 among companies on value.today
Worker positions
1
Median wage offered
$180 K
a year, full-time
Applications filed
1
Bolt Biotherapeutics, Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Assoc Director Drug Safety & Pharmacovigilance ScientistMedical Scientists, Except Epidemiologists1$180 K

Where: Waltham, MA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Bolt Biotherapeutics Inc

Layoffs at Bolt Biotherapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
70
2024–2025
Latest
20 people
2025-10-01
Bolt Biotherapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025·········20··20
2024····50·······50
Bolt Biotherapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
20 people (50% of workforce)Restructuring planSEC 8-K“The restructuring plan includes a reduction of the Company’s current workforce by approximately 20 employees, or approximately 50% of the Company’s workforce.”Filing
effective 38 peopleLayoffWARN noticeRedwood City, CaliforniaNotice list
50 people (50% of workforce)Restructuring planSEC 8-K“The restructuring plan includes a reduction of the Company’s current workforce by approximately 50 employees, or approximately 50% of the Company’s workforce.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Bolt Biotherapeutics, Inc. compares in Biotechnology

  • Market cap$16 M · higher than 15% of 726
  • Revenue$8 M · higher than 40% of 647
  • Net margin-610.2% · higher than 9% of 408
  • Revenue growth0.1% · higher than 45% of 438
  • Price / sales3.5× · lower than 73% of 339
  • Price / book0.6× · lower than 89% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Bolt Biotherapeutics, Inc.🇺🇸$16 M—-610.2%+0.1%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Bolt Biotherapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Bolt Biotherapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Bolt Biotherapeutics, Inc.? Suggest a correction